Decitabine shows anti-acute myeloid leukemia potential via regulating the miR-212-5p/CCNT2 axis

Lina Xing*, Jinhai Ren, Xiaonan Guo, Shukai Qiao, Tian Tian

Abstract: Previous research has revealed the involvement of microRNA-212-5p (miR-212-5p) and cyclin T2 (CCNT2) in acute myeloid leukemia (AML). However, whether the miR-212-5p/CCNT2 axis is required for the function of decitabine in AML has not been well elucidated. Quantitative reverse transcription-polymerase chain reaction was used to examine enrichment of miR-212-5p. The relationship between CCNT2 and miR-212-5p was verified by the luciferase reporter assay. Cell apoptosis was evaluated by flow cytometry and western blot. CCK-8 assay was performed to determine cell viability. Decitabine significantly repressed cell viability, while promoted cell apoptosis. Meanwhile, the expression levels of cyclinD1, CDK4, and Bcl-2 were suppressed in cells with decitabine exposure, but Bax and caspase-3 expression levels were upregulated. Besides, miR-212-5p upregulation had the similar function with decitabine in AML cell proliferation and apoptosis. Subsequently, restoration of CCNT2 attenuated miR-212-5p overexpression-induced effects in Kasumii-1 and SKNO-1 cells. In addition, miR-212-5p depletion reversed decitabine-induced CCNT2 downregulation. The miR-212-5p/CCNT2 axis had an implication in the anti-leukemic effect of decitabine in AML.

Keywords: decitabine, miR-212-5p, AML, CCNT2

1 Introduction

Acute myeloid leukemia (AML) is a malignant leukemia affecting adults [1,2]. Although great progression in AML treatment has been made, the prognosis and outcome of AML remain dismal.

Many studies have shown that hypomethylating agents contribute to the treatment of hematologic malignancies, including AML [3–5]. Decitabine, a DNA hypomethylating agent, is one of the most commonly utilized therapeutics for AML [6]. In AML cell lines, it has been observed that decitabine inhibits cell viability and promotes apoptosis [7]. However, the effect of decitabine is still limited. MicroRNAs (miRNAs) are widely reported to modulate cellular viability, survival, as well as differentiation, and act as the potential therapeutic targets for AML [8]. For instance, Yan et al. demonstrated low expression of miR-217 in AML in vivo, which may be a prognostic indicator for AML [9]. In another report, loss of miR-345-5p promoted proliferation and blocked apoptosis by targeting AKT2 in AML [10]. Previous studies pointed out that miR-29b overexpression could increase the antileukemic activity of decitabine [11,12]. Low expression of miR-29a was linked to the malignant progression in pediatric AML patients [13]. These findings supported the important roles of miRNAs in predicting prognosis of AML. More importantly, miRNAs may have the potential to synergize with decitabine to treat AML. Previous studies have revealed the protective role of miR-212-5p in various diseases, including AML [14,15]. These results further showed that miR-212-5p could regulate the proliferation and apoptosis of AML in vitro [15]. Cyclin T2 (CCNT2) is required for the RNA polymerase II-mediated transcription process [16,17]. More importantly, a previous investigation indicated that miR-192 suppressed cell viability and cell cycle progression as well as enhanced cell apoptosis in AML by targeting CCNT2 [18]. Although several findings have indicated the roles of miRNAs (including miR-212-5p) and CCNT2 in AML, the involvement of the miR-212-5p/CCNT2 pathway in the antileukemic activity of decitabine has not been fully understood.

In this study, we sought to address whether the miR-212-5p/CCNT2 pathway is required for the antiproliferative function of decitabine in AML.
2 Materials and methods

2.1 Cell culture and transfection

Cells (Kasumi-1 and SKNO-1 cell lines) were purchased from American Type Culture Collection (Manassas, VA, USA) and maintained in RPMI 1640 (Thermo Fisher Scientific, Waltham, MA, USA) containing 10% fetal bovine serum. CCNT2 overexpression plasmid (pc-CCNT2), pcDNA 3.0 vector (pc-NC), miR-212-5p mimic (agomiR-212-5p), negative control mimic (Scramble), miR-212-5p inhibitor (antagomiR-212-5p), and negative control inhibitor (antagomiR-NC) were constructed. In brief, 1 × 10^6 cells were plated into a 6-well plate, then the constructs were transfected into the cells using Lipofectamine 3000 (Thermo Fisher Scientific) following the manufacturer’s instruction. 24-72 hours upon transfection, the transfected cells were harvested for subsequent research.

2.2 Luciferase reporter assay

CCNT2 fragments including the wild-type (WT-CCNT2) or mutated (MUT-CCNT2) were cloned into the psiCHECK-2 vector. Cells were co-transfected with agomiR-212-5p or Scramble and WT-CCNT2 or MUT-CCNT2 using Lipofectamine 3000. The relative luciferase activity was quantified with the dual-luciferase reporter assay system (Promega, Madison, WI, USA).

2.3 Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) assay

Total RNA was extracted using Trizol reagent (Invitrogen, Carlsbad, CA, USA) and DNase I and quantified with Nanodrop 2000 (Thermo Fisher Scientific). Then, reverse transcription was performed using PrimeScript RT Reagent Kit (Takara, Dalian, China). qPCR was conducted using SYBR Green PCR Master Mix (BioSystems, Foster City, CA, USA). Beta-actin (β-actin) was employed as the internal control, which was the most stable reference gene in AML analyzed by GeNorm and NormFinder [19,20]. Relative expression levels of CCNT2 and miR-212-5p were calculated using the 2^−ΔΔCt method. The primer sequences are presented in Table 1.

2.4 Western blot

Total protein was extracted from cells using RIPA lysis buffer (Beyotime, Shanghai, China) containing phenylmethylsulfonyl fluoride (PMSF; Beyotime) and separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Samples were then transferred to polyvinylidene difluoride membranes (Millipore, Bedford, MA, USA). Afterward, the membranes were blocked with 5% skim milk for 1 h at room temperature. The membranes were incubated with the following primary antibodies at 4°C overnight: anti-CCNT2 (1:1,000; ab96133; Abcam, Cambridge, UK), anti-β-actin (1:2,500; ab8227; Abcam), anti-cyclinD1 (1:5,000; ab134175; Abcam), anti-CDK4 (1:1,000; ab108357; Abcam), anti-Bcl-2 (1:1,000; ab32124; Abcam), anti-Bax (1:1,000; ab32503; Abcam), and anti-caspase-3 (1:500; ab13847; Abcam); and then incubated with secondary antibody (1:5,000; ab205718; Abcam) for 1 h at room temperature. Protein bands were visualized using ECL kits (Thermo Fisher Scientific).

2.5 Cell Counting Kit-8 (CCK-8) assay

After decitabine (Sigma-Aldrich, Germany) treatment and/or miRNA and plasmid transfection, cells at a density of 5–6 × 10^5 per well (96-well plate) in 100 μL of

Table 1: The primers used in qRT-PCR

| Gene   | Primer sequence | Tm (°C) | Amplification efficiency (%) | Product size (bp) |
|--------|-----------------|---------|-------------------------------|-------------------|
| miR-212-5p | F: ACCCTGGCCTAGACTGCT  | 57.6 | 92.30 | 74 |
|         | R: GCAGGGTCCAGGTTATTC  | 56.8 | | |
| CCNT2  | F: GGAGTGAGGCGGCTAAGAG  | 59.9 | 94.70 | 84 |
|         | R: AGAGACATTGAGACGCTGTC  | 59.8 | | |
| U6     | F: TAGGATTATACATTGTAAGAGT | 51.8 | 93.50 | 119 |
|         | R: GTGTCCTACAGAATTTAAGGTTT | 55.4 | | |
| β-Actin| F: CTTCGCCGCGCCGAGAT  | 59.9 | 96.40 | 104 |
|         | R: CCACATAGGAATCTCTGAC  | 58.7 | | |
culture medium were tested. Ten microliters of the CCK-8 solution (Beyotime) were added into each well and incubated for 4 h. Absorbance was measured at 450 nm using a microplate reader (Bio-Rad, Hercules, CA, USA).

2.6 Cell apoptosis assay

The number of cells per sample was 1–5 × 10^6/mL. The cells were washed once with incubation buffer, resuspended with 100 µL of labeling solution (labeling solution: Annexin V-FITC and PI in the incubation buffer at a final concentration of 1 µg/mL), incubated for 15 min at room temperature, and collected by centrifugation at 1,000 rpm for 5 min. Apoptotic cells were detected using a flow cytometer (BD Biosciences, San Jose, CA, USA).

2.7 Statistical analysis

Statistical analysis in this study was performed using Graphpad 7.0 statistical software (Graphpad, San Diego, CA, USA). The differences were determined using Student’s
t-test or one-way ANOVA. P values less than 0.05 were considered statistically significant.

3 Results

3.1 Decitabine decreases proliferation while promotes apoptosis of AML cells

In this study, decitabine was used to treat AML cells. As shown in Figure 1a and b, various concentrations of decitabine were used to stimulate Kasumi-1 and SKNO-1 cells. Our data indicated that cell viability was significantly inhibited after treatment with different concentrations of decitabine. The results of flow cytometry further outlined that decitabine notably increased the cell apoptotic rate (Figure 1c and d). To expound the molecular basis of these processes, the expression levels of proliferation/apoptosis-related proteins were detected (Figure 2a and b). We found that cyclinD1 and CDK4, proliferation-related...
proteins, were decreased in decitabine-treated cells. Meanwhile, Bcl-2 expression was also downregulated. In contrast, the levels of Bax and caspase-3 were distinctly upregulated in cells exposed to decitabine. Decitabine at a concentration of 5 µM was selected for the following experiments. MiR-212-5p was significantly upregulated in decitabine-treated cells (Figure 3). These data implied that miR-212-5p may be related to the function of decitabine in AML cells.

3.2 MiR-212-5p upregulation decreases cell viability, while increases cell apoptosis

Then, we upregulated miR-212-5p expression in AML cells using agomiR-212-5p. The transfection efficiency demonstrated that the introduction of agomiR-212-5p distinctly upregulated the miR-212-5p level (Figure 4a). The agomiRNA-mediated overexpression of miR-212-5p inhibited cell viability (Figure 4b and c). In addition, the cell apoptotic rate was remarkably increased by miR-212-5p overexpression (Figure 4d). Simultaneously, the result of the western blot analysis of proliferation/apoptosis-related proteins was also consistent with that of CCK-8 and flow cytometry assays (Figure 5a and b), further confirming that the gain of miR-212-5p may participate in decitabine-induced proliferation suppression and apoptosis promotion in AML cells.

3.3 MiR-212-5p contains the binding sites with CCNT2

It is well known that miRNAs regulate cellular processes by repressing target genes. We searched the potential target gene of miR-212-5p using an online tool TargetScan. The data uncovered that miR-212-5p harbored binding sequences complementary to CCNT2 seed regions (Figure 6a). We further addressed whether mir-212-5p targets CCNT2. As a result, the transfection of agomiR-212-5p greatly decreased the luciferase activity of the WT-CCNT2 group, while no obvious change was observed in the
MUT-CCNT2 group (Figure 6b and c). As demonstrated in Figure 6d, the delivery of agomiR-212-5p induced the inhibition of the CCNT2 protein level. However, the interference of miR-212-5p elevated the CCNT2 level (Figure 6e).

3.4 Restoration of CCNT2 attenuates the effects of miR-212-5p upregulation in AML

We performed the rescue-of-function experiment to confirm the involvement of miR-212-5p/CCNT2 axis in the regulation of proliferation and apoptosis of AML. As displayed in Figure 7a and b, the protein level of CCNT2 was lower in miR-212-5p overexpressing cells than that of the control group, while it was rescued by forced expression of CCNT2. CCK-8 assay further indicated that elevated CCNT2 expression regained miR-212-5p upregulation-induced inhibition of cell viability (Figure 7c and d). When compared with the agomiR-212-5p + pc-NC group, cell apoptosis was blocked in the agomiR-212-5p + pc-CCNT2 group (Figure 7e and f). These results revealed that pc-CCNT2 transfection distinctly overturned the impact of miR-212-5p upregulation on cell viability and apoptosis.

Figure 5: Effect of miR-212-5p upregulation on the expression levels of proliferation- and apoptosis-related proteins in AML cells. (a and b) The protein levels of cyclinD1, CDK4, Bcl-2, Bax, and caspase-3 in cells transfected with agomiR-212-5p. *P < 0.05.
3.5 MiR-212-5p ablation overturns decitabine-induced CCNT2 downregulation

Finally, the level of CCNT2 in AML cells treated with decitabine and antagomiR-212-5p was also examined using qRT-PCR. In Kasumi-1 cells, we disclosed that the protein level of CCNT2 was inhibited in the decitabine group compared with that in the control group. However, the introduction of antagomiR-212-5p dramatically recuperated the decitabine-induced CCNT2 suppression (Figure 8a).

As expected, MiR-212-5p ablation overturned decitabine-induced CCNT2 downregulation in SKNO-1 cells (Figure 8b). Collectively, all these data implied that the miR-212-5p/CCNT2 axis may be responsible for the function of decitabine in AML, further demonstrating the potential of miR-212-5p combined with decitabine in AML treatment by inducing cell proliferation inhibition and apoptosis (Figure 9).

4 Discussion

AML develops in people of all ages, especially in the elderly, who have poor overall survival rates [2,21]. It has been well documented that decitabine has acceptable efficacy for the treatment of AML [22,23]. However, there are little data about the molecular mechanism of decitabine treatment of AML. Therefore, a deep understanding of the
related molecular mechanisms of decitabine in AML may contribute to the treatment of AML. In our study, we also confirmed the anti-AML activity of decitabine via evaluating cell viability and apoptosis. According to the cell viability of Kasumi-1 and SKNO-1 cells treated with different concentrations of decitabine for different times, decitabine at a concentration of 5 µM for 48 h was used to explore the regulatory mechanism of decitabine function in AML.

Accumulating studies supported that many miRNAs participate in the development of various diseases, including AML [8,9]. Emerging evidence has revealed the involvement of miR-212-5p in various diseases [14,24,25]. Researchers have reported that miR-212-5p prevents dopaminergic neuron death in the mouse model of Parkinson’s disease [24]. In another study, high level of miR-212-5p blocks epithelial–mesenchymal transition in breast cancer, thereby inhibiting cancer progression [26]. A study also revealed that downregulation of miR-212-5p is related to MIF-AS1-mediated promotion of proliferation and apoptosis inhibition in gastric cancer [27]. Recently, the previous study has demonstrated that the expression of miR-212-5p is low in AML patients and cells. They further indicated that the upregulation of miR-212-5p blocks cell viability and proliferation, while increases apoptosis in Kasumi-1 cells [15]. Consistently, we disclosed that the miR-212-5p level was elevated in cells exposed to different concentrations of decitabine. Moreover, gain of miR-212-5p induced cell viability promotion, as well as increased the cell apoptosis rate, implying that miR-212-5p may participate in the process of AML response to decitabine. The induced expression of miR-212-5p by decitabine and its role in AML suggested that miR-212-5p might serve as a potential biomarker in AML or in decitabine-treated AML; however, this still needs to be verified by further clinical test.

Figure 7: Effect of CCNT2 overexpression on miR-212-5p upregulation-induced effects in AML cells. (a and b) Cells were co-transfected with agomir-212-5p and CCNT2 overexpression plasmid (pc-CCNT2) and then subjected to western blot analysis of CCNT2. (c–f) Cell viability and apoptosis were determined by CCK-8 assay and flow cytometry, respectively. *P < 0.05.
An increasing number of miRNA–mRNA networks was identified to be associated with AML [28,29]. A previous study stated that miR-142-3p may play a suppressor role in the development of gastric cancer via downregulating CCNT2 [30]. A study confirmed that CCNT2 act as a target of miR-15a to block spermatogenesis [31]. MiR-297c-5p impedes cell proliferation via negatively affecting CCNT2 expression in oligodendrocyte progenitor cells [32]. Recent evidence showed that CCNT2 may act as the target of miR-192 and participate in the progression of AML [18]. But whether CCNT2 is associated with the miR-212-5p-mediated function has not been elaborated. Interestingly, results from this study provided the evidence that CCNT2 contained the binding sites with miR-212-5p and the expression of CCNT2 could be impeded by miR-212-5p, referring that CCNT2 may have an implication in the function of miR-212-5p in decitabine-treated cells. Subsequently, in rescue-of-function experiment, the function of miR-212-5p overexpression to inhibit cell viability and promote cell apoptosis was blocked by CCNT2 upregulation in AML, and these results suggested that miR-212-5p effected the behavior of AML cells via targeting CCNT2. In further experiments, CCNT2 was visibly decreased in AML cells treated with decitabine; nevertheless, the decitabine-induced suppression of CCNT2 was relieved by downregulation of miR-212-5p. In summary, these experiments proved that decitabine repressed cell proliferation and enhanced apoptosis via inducing miR-212-5p expression to downregulate CCNT2 in AML (Figure 9).

There are some limitations in this study. It is vital to explore the detailed molecular mechanisms of the miR-212-5p/CCNT2 axis in the treatment of AML. At the same time, the role of CCNT2 alone should be anatomized in future. In addition, whether the miR-212-5p/CCNT2 pathway axis influences other cell biological processes in decitabine-treated AML cells also requires more intensive research. Their function should be addressed in vivo in future.
In conclusion, these findings shed light on that miR-212-5p may serve as a potential target of AML therapy. MiR-212-5p/CCNT2 pathway is a novel mechanism of decitabine-induced response in AML cells, which could bridge an important gap in knowledge of decitabine treatment for AML. Meanwhile, our data also provided the theoretical basis for the pathogenesis of AML.

Acknowledgments: This work was supported by Clinical study on the treatment of medullary tumors by decitabine (grant no. 20180293).

Conflict of interest: The authors state no conflict of interest.

Data availability statement: The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

References

[1] De Kouchkovsky I, Abdul-Hay M. Acute myeloid leukemia: a comprehensive review and 2016 update. Blood Cancer J. 2016;6(7):e441.

[2] Shallis RM, Wang R, Davidoff A, Ma X, Zeidan AM. Epidemiology of acute myeloid leukemia: recent progress and enduring challenges. Blood Rev. 2019;36:70–87.

[3] Lindblad KE, Goswami M, Hourigan CS, Oetjen KA. Immuno logical effects of hypomethylating agents. Expert Rev Hematol. 2017;10(8):745–52.

[4] Gardin C, Dombret H. Hypomethylating agents as a therapy for AML. Curr Hematol Malig Rep. 2017;12(1):1–10.

[5] Gbolahan OB, Zeidan AM, Stahl M, Abu Zaid M, Farag S, Paczysny S, et al. Immunotherapeutic concepts to target acute myeloid leukemia: focusing on the role of monoclonal antibodies, hypomethylating agents and the leukemic microenvironment. Int J Mol Sci. 2017;18(8):1660.

[6] He PF, Zhou JD, Yao DM, Ma JC, Wen XM, Zhang ZH, et al. Efficacy and safety of decitabine in treatment of elderly patients with acute myeloid leukemia: a systematic review and meta-analysis. Oncotarget. 2017;8(25):41498–507.

[7] Mao J, Li S, Zhao H, Zhu Y, Hong M, Zhu H, et al. Effects of chidamide and its combination with decitabine on proliferation and apoptosis of leukemia cell lines. Am J Transl Res. 2018;10(8):2567–78.

[8] Wallace JA, O’Connell RM. MicroRNAs and acute myeloid leukemia: therapeutic implications and emerging concepts. Blood. 2017;130(11):1290–301.

[9] Yan J, Wu G, Chen J, Xiong L, Chen G, Li P. Downregulated miR-217 expression predicts a poor outcome in acute myeloid leukemia. Cancer Biomark. 2018;22(1):73–8.

[10] Ying X, Zhang W, Fang M, Zhang W, Wang C, Han L. miR-345-5p regulates proliferation, cell cycle, and apoptosis of acute myeloid leukemia cells by targeting AKT2. J Cell Biochem. 2019;120(2):1620–9.

[11] Mims A, Walker AR, Huang X, Sun J, Wang H, Santhanam R, et al. Increased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: a novel epigenetic-targeting approach in acute myeloid leukemia. Leukemia. 2013;27(4):871–8.

[12] Blum W, Garzon R, Kliosovic RB, Schwind S, Walker A, Geyer S, et al. Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci USA. 2010;107(16):7473–8.

[13] Zhu C, Wang Y, Kuai W, Sun X, Chen H, Hong Z. Prognostic value of miR-29a expression in pediatric acute myeloid leukemia. Clin Biomol. 2013;46(1–2):49–53.

[14] Jia Q, Chang J, Hong Q, Zhang J, Zhou H, Chen FH. MiR-212-5p exerts a protective effect in chronic obstructive pulmonary disease. Discovery Med. 2018;26(144):173–83.

[15] Lin JF, Zeng H, Zhao QJ. MiR-212-5p regulates the proliferation and apoptosis of AML cells through targeting FZD5. Eur Rev Med Pharmacol Sci. 2018;22(23):8415–22.

[16] Kohoutek J, Li Q, Blazek D, Luò Z, Jiang H, Peterlin BM. Cyclin T2 is essential for mouse embryogenesis. Mol Cell Biol. 2009;29(12):3280–5.

[17] Bauml S, Lolli G, Lowe ED, Troiani S, Rusconi L, Bullock AN, et al. The structure of P-TEFb (CDK9/cyclin T1), its complex with flavopiridol and regulation by phosphorylation. EMBO J. 2008;27(13):1907–18.

[18] Ke S, Li RC, Lu J, Meng FK, Feng YK, Fang MH. MicroRNA-192 regulates cell proliferation and cell cycle transition in acute myeloid leukemia via interaction with CCNT2. Int J Hematol. 2017;106(2):258–65.

[19] Lee C, Yiau KXS, Lee LJ, Chong PP, Chang KM, Abdullah M. Selection of reference genes for quantitative studies in acute myeloid leukaemia. Malaysian J Pathol. 2019;41(3):313–26.

[20] Li H, Chen C, Yao H, Li X, Yang N, Qiao J, et al. Identification of suitable reference genes for mRNA studies in bone marrow in a mouse model of hematopoietic stem cell transplantation. Transplant Proc. 2016;48(8):2826–32.

[21] Gran B, Weisdorf DJ. Survival for older patients with acute myeloid leukemia: a population-based study. Haematologica. 2012;97(12):1916–24.

[22] Park H, Chung H, Lee J, Jang J, Kim Y, Kim SJ, et al. Decitabine as a first-line treatment for older adults newly diagnosed with acute myeloid leukemia. Yonsei Med J. 2017;58(1):35–42.

[23] Levine LB, Roddy JV, Kim M, Li J, Phillips G, Walker AR. A comparison of toxicities in acute myeloid leukemia patients with and without renal impairment treated with decitabine. J Oncol Pharm Pract. 2018;24(4):290–8.

[24] Sun S, Han X, Li X, Song Q, Lu M, Jia M, et al. MicroRNA-212-5p prevents dopaminergic neuron death by inhibiting SIRT2 in MPTP-induced mouse model of Parkinson’s disease. Front Mol Neurosci. 2018;11:381.

[25] Dix A, Czakai K, Leonhardt I, Schäferhoff K, Bonin M, Guthke R, et al. Specific and novel microRNAs are regulated as response to fungal infection in human dendritic cells. Front Microbiol. 2017;8:270.

[26] Lv ZD, Yang DX, Liu XP, Jin LY, Wang XG, Yang ZC, et al. MiR-212-5p suppresses the epithelial-mesenchymal transition in triple-
negative breast cancer by targeting Prrx2. Cell Physiol Biochem. 2017;44(5):1785–95.

[27] Li L, Li Y, Huang Y, Ouyang Y, Zhu Y, Wang Y, et al. Long non-coding RNA MIF-AS1 promotes gastric cancer cell proliferation and reduces apoptosis to upregulate NDUFA4. Cancer Sci. 2018;109(12):3716–25.

[28] Wang Y, Wang C, Chen C, Wu F, Shen P, Zhang P, et al. Long non-coding RNA NEAT1 regulates epithelial membrane protein 2 expression to repress nasopharyngeal carcinoma migration and irradiation-resistance through miR-101-3p as a competing endogenous RNA mechanism. Oncotarget. 2017;8(41):70156–71.

[29] Zhou JD, Li XX, Zhang TJ, Xu ZJ, Zhang ZH, Gu Y, et al. MicroRNA-335/ID4 dysregulation predicts clinical outcome and facilitates leukemogenesis by activating PI3K/Akt signaling pathway in acute myeloid leukemia. Aging. 2019;11(10):3376–91.

[30] Wang Y, Cao Z, Wang L, Liu S, Cai J. Downregulation of microRNA-142-3p and its tumor suppressor role in gastric cancer. Oncol Lett. 2018;15(5):8172–80.

[31] Teng Y, Wang Y, Fu J, Cheng X, Miao S, Wang L. Cyclin T2: a novel miR-15a target gene involved in early spermatogenesis. FEBS Lett. 2011;585(15):2493–500.

[32] Kuypers NJ, Bankston AN, Howard RM, Beare JE, Whittemore SR. Remyelinating oligodendrocyte precursor cell miRNAs from the Sfmbt2 cluster promote cell cycle arrest and differentiation. J Neurosci. 2016;36(5):1698–710.